1
|
Zettler ME. FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications. Target Oncol 2023; 18:777-792. [PMID: 37477750 DOI: 10.1007/s11523-023-00982-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/19/2023] [Indexed: 07/22/2023]
Abstract
BACKGROUND The development of molecularly targeted oncology drugs for tissue-agnostic indications represents a new paradigm, but marketing authorization may carry additional risks due to uncertainties about extrapolating drug safety and efficacy, and biomarker test accuracy, to unstudied tumor types. OBJECTIVE To determine tumor types represented and method of mutation identification in trials supporting the US Food and Drug Administration (FDA) approvals of tissue-agnostic drugs, and to describe post-marketing requirements and commitments (PMRs/PMCs) issued for studies to evaluate additional tumor types and to validate companion diagnostic devices. METHODS For each tissue-agnostic drug approval identified via the FDA's Hematology/Oncology Approvals and Safety Notifications website, prescribing information, approval packages, and letters were retrieved from the Drugs@FDA website. Characteristics of approvals, details of supporting trials, and PMRs/PMCs for clinical trials and diagnostic tests were extracted. RESULTS Six drugs were approved for seven tissue-agnostic indications between 2017 and 2022, with 9-15 different tumor types represented in trials supporting approvals. Only one approval prospectively utilized a commercial assay to identify the molecular alteration of interest in tumor samples. All seven approvals were issued PMRs for trials with additional tumor types, and six of seven were issued PMCs for studies to support labeling for companion diagnostic devices. CONCLUSION The number of patients and cancer subtypes in trials supporting tissue-agnostic oncology drug approvals varied by mutation. Most drug approvals did not have concurrent approval of a diagnostic test. Post-marketing studies play a critical role in confirming clinical benefit and ensuring companion diagnostic device performance across a broader range of tumor types.
Collapse
|
2
|
Abstract
BACKGROUND : The 21st Century Cures Act of 2016 included provisions for the Food and Drug Administration (FDA) to evaluate the potential for real-world evidence (RWE) to support or fulfill post-approval study requirements. This study reviewed post-marketing requirement (PMR) and post-marketing commitment (PMC) obligations for oncology drugs approved by the FDA post-Cures Act to identify those with RWE components. METHODS : Approval letters issued by the FDA between 2017-2020 for oncology drugs were systematically analyzed for PMRs or PMCs with requests for RWE. For each PMR/PMC identified, the characteristics of the approvals, the PMRs/PMCs, and the RWE requested were reviewed. RESULTS : Of 189 oncology drug approvals with 456 associated PMRs/PMCs, a total of 15 PMRs/PMCs specified RWE. Compared with all oncology drug approvals, the 14 approvals with PMRs/PMCs requesting RWE were more frequently accelerated approvals, for new therapies, with orphan indications. All 15 PMRs/PMCs requested real-world safety data, with 3 also requesting real-world effectiveness data. RWE requested included post-marketing safety reports, prospective observational studies, expanded access study data, and registry data. CONCLUSION : As a greater proportion of safety and efficacy data generation for oncology drugs shifts to the post-marketing setting, RWE has the potential to become an integral component of PMR/PMC fulfillment.
Collapse
|
3
|
Zettler ME. The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs. Expert Rev Anticancer Ther 2022; 22:317-321. [PMID: 35051348 DOI: 10.1080/14737140.2022.2032664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND The Research to Accelerate Cures and Equity (RACE) for Children Act of 2017 authorized the Food and Drug Administration (FDA) to require pediatric clinical trials for new oncology drugs with relevant molecular targets. This study reviewed oncology drug approvals within the first year after the new legislation came into effect, to evaluate the impact on development of molecularly targeted oncology drugs for pediatric cancers. RESEARCH DESIGN AND METHODS For new oncology drugs approved by the FDA between 08/18/2020-08/18/2021, drug approval packages, letters and prescribing information were reviewed for the submission and approval dates, indication and molecular target of the drug, and post-marketing requirements that included pediatric clinical trials. RESULTS Within the 1-year period, 17 new oncology drugs were approved, but only 5 had been submitted after 08/18/2020. Three of the 5 (60.0%) had requirements for pediatric trials under the RACE Act. None of the 12 submitted prior to 08/18/2020 had pediatric trial requirements, but 11 (91.7%) had molecular targets that would have made them candidates under the RACE Act. Nine of the 17 approvals (52.9%) had pediatric trials registered on clinicaltrials.gov. CONCLUSIONS Early evidence suggests that while some pediatric development of oncology drugs was initiated without FDA request, the RACE Act was effective at closing the loopholes of previous legislation and creating new opportunities for innovation in developing therapies for childhood cancers.
Collapse
|
4
|
Gajra A, Zettler ME, Miller KA, Frownfelter JG, Showalter J, Valley AW, Sharma S, Sridharan S, Kish JK, Blau S. Impact of Augmented Intelligence on Utilization of Palliative Care Services in a Real-World Oncology Setting. JCO Oncol Pract 2022; 18:e80-e88. [PMID: 34506215 PMCID: PMC8758123 DOI: 10.1200/op.21.00179] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 07/12/2021] [Accepted: 08/06/2021] [Indexed: 01/03/2023] Open
Abstract
PURPOSE For patients with advanced cancer, timely referral to palliative care (PC) services can ensure that end-of-life care aligns with their preferences and goals. Overestimation of life expectancy may result in underutilization of PC services, counterproductive treatment measures, and reduced quality of life for patients. We assessed the impact of a commercially available augmented intelligence (AI) tool to predict 30-day mortality risk on PC service utilization in a real-world setting. METHODS Patients within a large hematology-oncology practice were scored weekly between June 2018 and October 2019 with an AI tool to generate insights into short-term mortality risk. Patients identified by the tool as being at high or medium risk were assessed for a supportive care visit and further referred as appropriate. Average monthly rates of PC and hospice referrals were calculated 5 months predeployment and 17 months postdeployment of the tool in the practice. RESULTS The mean rate of PC consults increased from 17.3 to 29.1 per 1,000 patients per month (PPM) pre- and postdeployment, whereas the mean rate of hospice referrals increased from 0.2 to 1.6 per 1,000 PPM. Eliminating the first 6 months following deployment to account for user learning curve, the mean rate of PC consults nearly doubled over baseline to 33.0 and hospice referrals increased 12-fold to 2.4 PPM. CONCLUSION Deployment of an AI tool at a hematology-oncology practice was found to be feasible for identifying patients at high or medium risk for short-term mortality. Insights generated by the tool drove clinical practice changes, resulting in significant increases in PC and hospice referrals.
Collapse
Affiliation(s)
- Ajeet Gajra
- Cardinal Health Specialty Solutions, Dublin, OH
| | | | | | | | | | | | | | | | | | - Sibel Blau
- Rainier Hematology Oncology/Northwest Medical Specialties, Seattle, WA
| |
Collapse
|
5
|
Abstract
OBJECTIVE Cancer survival rates have improved over the past few decades, yet socioeconomic disparities persist. Social determinants of health (SDOH) have consistently been shown to correlate with health outcomes. The objective of this study was to characterise oncologists' perceptions of the impact of SDOH on their patients, and their opinions on how these effects could be remediated. DESIGN Cross-sectional survey of physicians. SETTING Web-based survey completed prior to live meetings held between February and April 2020. PARTICIPANTS Oncologists/haematologists from across the USA. EXPOSURE Clinical practice in a community-based or hospital-based setting. MAIN OUTCOME AND MEASURE Physician responses regarding how SDOH affected their patients, which factors represented the most significant barriers to optimal health outcomes and how the impact of SDOH could be mitigated through assistance programmes. RESULTS Of the 165 physicians who completed the survey, 93% agreed that SDOH had a significant impact on their patients' health outcomes. Financial security/lack of insurance and access to transportation were identified most often as the greatest barriers for their patients (83% and 58%, respectively). Eighty-one per cent of physicians indicated that they and their staff had limited time to spend assisting patients with social needs, and 76% reported that assistance programmes were not readily accessible. Government organisations, hospitals, non-profit organisations and commercial payers were selected by 50% or more of oncologists surveyed as who should be responsible for delivering assistance programmes to patients with social needs; 42% indicated that pharmaceutical manufacturers should also be responsible. CONCLUSION Our survey found that most oncologists were aware of the impact of SDOH on their patients but were constrained in their time to assist patients with social needs. The physicians in our study identified a need for more accessible assistance programmes and greater involvement from all stakeholders in addressing SDOH to improve health outcomes.
Collapse
Affiliation(s)
| | | | | | - Ajeet Gajra
- Specialty Solutions, Cardinal Health Inc, Dublin, Ohio, USA
- Department of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA
| |
Collapse
|
6
|
Gajra A, Zettler ME, Miller KA, Blau S, Venkateshwaran SS, Sridharan S, Showalter J, Valley AW, Frownfelter JG. Augmented intelligence to predict 30-day mortality in patients with cancer. Future Oncol 2021; 17:3797-3807. [PMID: 34189965 DOI: 10.2217/fon-2021-0302] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Aim: An augmented intelligence tool to predict short-term mortality risk among patients with cancer could help identify those in need of actionable interventions or palliative care services. Patients & methods: An algorithm to predict 30-day mortality risk was developed using socioeconomic and clinical data from patients in a large community hematology/oncology practice. Patients were scored weekly; algorithm performance was assessed using dates of death in patients' electronic health records. Results: For patients scored as highest risk for 30-day mortality, the event rate was 4.9% (vs 0.7% in patients scored as low risk; a 7.4-times greater risk). Conclusion: The development and validation of a decision tool to accurately identify patients with cancer who are at risk for short-term mortality is feasible.
Collapse
Affiliation(s)
- Ajeet Gajra
- Cardinal Health Specialty Solutions, Dublin, OH 43017, USA
| | | | | | - Sibel Blau
- Rainier Hematology Oncology/Northwest Medical Specialties, Tacoma, WA 98405, USA
| | | | | | | | - Amy W Valley
- Cardinal Health Specialty Solutions, Dublin, OH 43017, USA
| | | |
Collapse
|
7
|
Savill KMZ, Zettler ME, Feinberg BA, Jeune-Smith Y, Gajra A. Awareness and utilization of tumor mutation burden (TMB) as a biomarker for administration of immuno-oncology (I-O) therapeutics by practicing community oncologists in the United States (U.S.). J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.2608] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2608 Background: TMB, a measurement of the number of mutations carried by tumor cells, is emerging as a biomarker for the identification of patients who may benefit from certain I-O-based therapies. TMB-high (TMB-H) tumors, defined by the detection of ≥10 mutations/megabase (mut/Mb) in tumor cells using a tissue-based assay such as the FoundationOneCDx (F1CDx) assay (Foundation Medicine, Inc.), may be more likely to respond to some I-O therapies. Higher neoantigen loads of TMB-H tumors have been proposed to contribute to increased responsiveness of TMB-H tumors to certain I-O therapeutics. Pembrolizumab was approved by the FDA on June 16, 2020 for the treatment of adult and pediatric patients with unresectable or metastatic TMB-H tumors, as determined by F1CDx, based on results from the KEYNOTE-158 trial (NCT02628067), which demonstrated that 50% of patients with TMB-H tumors had response durations of ≥24 months, with objective response rates in TMB-H vs. non-TMB-H patients of 29% and 6%, respectively (Marabelle et al, The Lancet Oncology, 2020). This survey-based study aimed to evaluate awareness and utilization of TMB as a biomarker for I-O therapeutics among practicing community oncologists in the U.S. Methods: Questions related to awareness and utilization of TMB as a biomarker for I-O therapeutics were developed by two medical oncologists (AG and BF) and presented to community oncologists in a web-based survey prior to virtual meetings held between October and November 2020. Descriptive statistics were used to analyze the results. Results: Of the 193 participating providers geographically distributed across the U.S., 15% reported being unaware of either the concept of TMB in I-O therapy or how to use the information clinically. 39% of these providers reported testing ≤25% of patients with advanced cancer for TMB, including 8% who do not test for TMB at all. Misconceptions regarding TMB identified among participating providers included the belief that high TMB is considered to be > 5 mut/Mb among 20% of providers, that TMB is essentially the same as MSI-high among 8% of providers, and that there are no therapies with FDA approval based on TMB among 15% of providers. Further, 37% of the participants did not identify pembrolizumab as an agent approved for the treatment of solid tumors based on TMB-H status. Conclusions: These findings demonstrate that there is a knowledge gap regarding the definition of TMB, testing for TMB, as well as implementation of TMB status in clinical decision making. Education directed towards community oncology providers regarding TMB and its use as a predictive biomarker for I-O therapy may improve its utilization and adoption in solid tumors to improve patient outcomes.
Collapse
|
8
|
Gajra A, Zettler ME, Ellis AR, Miller KA, Frownfelter JG, Valley AW, Blau S. Outcomes among patients with cancer previously identified as being at risk for 30-day mortality using augmented intelligence. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.12031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
12031 Background: An augmented intelligence (AI) tool using a machine learning algorithm was developed and validated to generate insights into risk for short-term mortality among patients with cancer. The algorithm, which scores patients every week as being at low, medium or high risk for death within 30 days, allowing providers to potentially intervene and modify care of those at medium to high risk based on established practice pathways. Deployment of the algorithm increased palliative care referrals in a large community hematology/oncology practice in the United States (Gajra et al, JCO 2020). The objective of this retrospective analysis was to evaluate the differences in survival and healthcare utilization (HCU) outcomes of patients previously scored as medium or high risk by the AI tool. Methods: Between 6/2018 – 10/2019, the AI tool scored patients on a weekly basis at the hematology/oncology practice. In 9/2020, a chart review was conducted for the 886 patients who had been identified by the algorithm as being at medium or high risk for 30-day mortality during the index period, to determine outcomes (including death, emergency department [ED] visits, and hospital admissions). Data are presented using descriptive statistics. Results: Of the 886 at-risk patients, 450 (50.8%) were deceased at the time of follow-up. Of these, 244 (54.2%) died within the first 180 days of scoring as at-risk, with median time to death 68 days (IQR 99). Among the 255 patients scored as high risk, 171 (67.1%) had died, vs. 279 (44.2%) of the 631 patients who were scored as medium risk (p < 0.001). Of the 601 patients who were scored more than once during the index period as medium or high risk, 342 (56.9%) had died, vs. 108 (37.9%) of the 285 who were scored as at risk only once (p < 0.001). A total of 363 patients (43.1%) had at least 1 ED visit, and 346 patients (41.1%) had at least 1 hospital admission. There was no difference in the proportion of patients scored as high risk compared with those scored as medium risk in ED visits (104 of 237 [43.9%] vs. 259 of 605 [42.8%], p = 0.778) or hospital admissions (100 of 237 [42.2%] vs. 246 of 605 [40.7%], p = 0.684, respectively). Compared with patients scored as medium or high risk only once during the index period, patients who were scored as at-risk more than once had more ED visits (282 of 593 [47.6%] vs. 81 of 249 [32.5%], p < 0.001) and hospital admissions (269 of 593 [45.4%] vs. 77 of 249 [30.9%], p < 0.001). Conclusions: This follow-up study found that half of the patients identified as at-risk for short-term mortality during the index period were deceased, with greater likelihood associated with high risk score and being scored more than once. Over 40% had visited an ED or were admitted to hospital. These findings have important implications for the use of the algorithm to guide treatment discussions, prevent acute HCU and to plan ahead for end of life care in patients with cancer.
Collapse
Affiliation(s)
| | | | - Amy R. Ellis
- Rainier Hematology Oncology/Northwest Medical Specialties, Seattle, WA
| | | | | | | | - Sibel Blau
- Rainier Hematology Oncology/Northwest Medical Specialties, Seattle, WA
| |
Collapse
|
9
|
Swain RS, Zettler ME, Jeune-Smith Y, Feinberg BA, Gajra A. Cooperative group and pharmaceutical sponsored clinical trials: Perceptions of U.S. community oncologists. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e13571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13571 Background: Many community-based oncologists in the US participate in clinical trials. These trials largely fall into two categories: trials run by cooperative (co-op) groups, funded and supported by the National Cancer Institute and trials developed, and supported by the pharmaceutical (pharma) industry. This study aimed to assess participation in, and perceptions regarding, co-op versus pharma trials among US community oncologists. Methods: We invited healthcare providers (HCP) across the continental US to attend 4 virtual meetings held between September and November 2020. Participants submitted their demographic information and responses to targeted questions regarding their opinions about co-op- and pharma-sponsored trials via a web-based pre-meeting survey. We evaluated participant HCP practice demographics and survey responses using descriptive statistics. Results: Of 259 surveyed participants, HCPs specialized in hematology-oncology (57%) and medical oncology (40%) with mean (median) 19 (18) years’ clinical experience. Most HCPs (178; 69%) reported participating in clinical research, and of these, 137 (77%) participated in co-op-led and 156 (88%) participated in pharma-led clinical research. HCPs preferred participating in both pharma and co-op (49%), pharma only (22%), and co-op only (11%) trials, while 18% preferred not to participate. Co-op trials were considered more prestigious to lead (86%), less likely to imply a conflict of interest (59%), and to address more pertinent questions (58%), while pharma trials had perceived advantages of better compensation (61%) and superior efficiency (48%). Co-op trials were perceived as not being financially sustainable (69%) and slower to accrue patients (85%) than pharma-led trials. Relatedly, in a hypothetical scenario of competing trials with identical design, the majority (60%) of HCPs preferred enrolling a loved one in a co-op trial. HCPs practicing in facilities with academic affiliation (34%) and in non-academic (66%) settings reported similar perceptions about co-op- and pharma-led trials; though, HCPs in academic settings were more likely to participate in clinical research compared to those in non-academic settings (82% vs. 62% [ P=0.001], respectively). Conclusions: In our survey of experienced HCPs, co-op-led clinical trials were perceived generally more favorably than pharma-led trials, even with concerns regarding cost, feasibility, and slower recruitment. However, despite their preference for co-op trials, HCPs were more likely to participate in pharma-led trials. Almost a third of surveyed HCPs are not participating in clinical trials and a fifth do not wish to. These findings can inform stakeholders (co-op trial leadership, pharma drug development teams, and patient advocacy groups) regarding appropriate education, design, and messaging regarding future clinical trials in oncology.
Collapse
|
10
|
Zettler ME, Lee CH, Gajra A, Feinberg BA. Assessment of objective response rate (ORR) by investigator versus blinded independent central review in pivotal trials of drugs approved for solid tumor indications. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e13570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13570 Background: Objective response rate (ORR), defined as the proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST), is the most common endpoint used in pivotal trials supporting FDA approval of cancer drugs for solid tumor indications. Blinded independent central review (BICR) is frequently employed in clinical trials to minimize bias in evaluation of response rate, as historically, assessment of response by investigators (INV) has been shown to overestimate treatment effect. In this study, we analyzed the variability in assessment of ORR between INV and BICR in trials supporting recent Food and Drug Administration (FDA) approvals of drugs for solid tumor indications. Methods: The FDA’s novel drug approvals (2015-2019) were reviewed to identify drugs receiving primary approval for solid tumor indications. Drug approval packages accessed via the Drugs@FDA database and primary publications for the pivotal trials accessed via PubMed were reviewed for investigator-assessed and BICR-assessed ORR. For trials reporting both assessments, the difference between INV and BICR ORR was determined across all study arms. Data are presented using descriptive statistics. Results: A total of 36 drugs received primary approval for the treatment of solid tumors between 2015 and 2019. Of the 40 supporting trials, ORR was the primary endpoint for 21 (52.5%), progression-free survival for 13 (32.5%), and overall survival for 2 (5.0%). ORR was evaluated in 35 of the 40 trials (87.5%). Eight (22.9%) of the 35 trials evaluated INV ORR only, 5 (14.3%) evaluated BICR ORR only, and 22 (62.9%) evaluated both INV and BICR ORR. Among the 22 trials (29 arms in total), the mean difference between BICR- and INV-assessed ORR was -4.3% (95% CI: -6.4, -2.3); the range was -13.1 to 5. INV-assessed ORR was greater than BICR-assessed ORR in 22 of 29 arms (75.9%). The mean difference between BICR- and INV-assessed ORR among the 6 arms representing placebo or active control was -6.0 (95% CI: -11.0, -0.9), compared with -3.9 (95% CI: -6.3, -1.5) among the 23 experimental arms. Conclusions: Compared with BICR, INV overestimated ORR in three-quarters of the trial arms, including those representing control and experimental treatments. Despite this variability, for one fifth of the trials supporting approval of drugs to treat solid tumors, INV was the only method used to assess ORR. For consistency, and the ability to make relative cross-trial comparisons of ORR between agents, BICR should be considered for evaluation of tumor response in all registrational trials.
Collapse
|
11
|
Balanean A, Falkenstein A, Zettler ME, Klink AJ, Savill KMZ, Kish J, Brown-Bickerstaff C, Jeune-Smith Y, Gajra A. Racial disparity in uterine cancer treatment and survival: A matter of Black women’s lives. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.6550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6550 Background: Despite similar incidence rates of uterine cancer (UC) in Black and White women, the former have worse prognosis and survival. Absence of denominator correction for UC hysterectomy (prevalence varies within the United States [US] by race/region) may underestimate incidence. The objective of this study is to compare treatment and survival of patients with UC by race in a large, contemporary, population-based study with at least 5 years of follow-up. Methods: With the latest available data from the Surveillance, Epidemiology, and End Results database, comparisons between Black and White patients were made using chi-square and Mann-Whitney tests. Cox proportional hazards regression estimated the adjusted risk of mortality by including age at diagnosis, race, US region, tumor histology/stage/grade, and receipt of hysterectomy as covariates. Results: A total of 105,036 women (11,028 Black and 94,008 White) newly diagnosed with UC in 2000-2013 and followed through 2018 were identified. Median age at diagnosis was 62 years, and more patients in the South were Black (41% vs 17%, P<.0001). Higher rates of type 2 (15% vs 6%), late-stage (44% vs 28%), and high-grade (48% vs 25%) tumors at diagnosis were also found in Black women (all Ps<.0001; Table). Compared with White women, Black women had lower 5-year survival rate (18% vs 37%, P<.0001), shorter survival (median 49 vs 78 months, P<.0001), and higher adjusted mortality risk (hazard ratio [HR]: 1.3, 95% CI: [1.3, 1.4], P<.0001). Lack or unknown status of hysterectomy was also associated with higher death risk (HR: 3.6, 95% CI: [3.4, 3.9], P<.0001). Conclusions: Correcting for hysterectomy attenuates racial disparity in incidence; however, black women have inferior outcomes primarily due to increased aggressive histology, late-stage, and high-grade tumors as well as decreased use of hysterectomy. Underestimation of at-risk populations may be misdirecting cancer control efforts, highlighting the importance of accurate reporting to inform potential treatment adaptations. Next steps are to assess cancer-specific mortality with Fine-Gray competing risk models.[Table: see text]
Collapse
|
12
|
Gajra A, Zettler ME. Age-based disparities in clinical trials supporting FDA approval of therapies for solid tumors. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e18534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e18534 Background: Cancer of any site is most frequently diagnosed among adults age 65 years and older, however older adults have historically been under-represented in clinical trials for oncology drugs (difference in median age [DMA] −6.49 years among clinical trials for breast, prostate, lung and colorectal cancer from 1994-2015 [Ludmir et al, JAMA Oncology 2019]). Representation in registrational trials, which are the basis for drug approval and inform the prescribing information, is of particular importance as age‐related differences may affect response and toxicity. We conducted an analysis of the trials supporting recent Food and Drug Administration approvals of new therapies for the treatment of solid tumors to assess the median age of participants and compare it to the median age of patients in the real world for each malignancy. Methods: Prescribing information for novel therapies that received primary approval for solid tumor indications between 2015 and 2019 was reviewed, and the median age in the evaluable population of the supporting clinical trials was abstracted. Median age estimates among adults for each indication in the general population were obtained from the Surveillance, Epidemiology and End Results database or the published literature. The DMA was calculated for each trial by subtracting the median age in the real-world population from the median age in the trial. Characteristics of trial protocols were obtained from approval packages accessed in the Drugs@FDA database. Data are presented using descriptive statistics. Results: A total of 35 solid tumor drugs were approved based on 38 trials, with 15859 patients in the evaluable populations. Less than half of the trials were phase 3 (16; 42%) or were randomized with a control group (18; 47%). On average, the median age of the trial participants was 2.6 years younger than the median age of the disease populations (95% CI: -1.4, -3.9 years; p < 0.01). For indications with > 1 trial, those with the greatest disparities were in melanoma (mean DMA -6.5), urothelial carcinoma (-5.8), and lung cancer (-4.1). The DMA among phase 3 trials was -1.8, vs. -3.2 among phase 1 and 2 trials. None of the protocols for the trials specified upper age limits, however 23 (61%) required an ECOG performance status (PS) ≤1, and all trials had eligibility restrictions related to organ function or comorbidities. Conclusions: In this contemporary analysis of registrational trials across all solid tumor indications, we found that the median age of clinical trial participants was nearly 3 years younger than their real-world counterparts. No trial protocols had upper age limits, however most restricted PS, organ impairment or the presence of comorbidities, which may have impacted older patients’ eligibility to participate. Although inclusion of older adults in clinical trials appears to have improved in recent years, changes to trial design may help to ensure adequate representation.
Collapse
|
13
|
Jeune-Smith Y, Zettler ME, Fortier S, Rupard S, Gajra A, Feinberg BA. Postmarketing requirements for drugs approved by the Food and Drug Administration for the treatment of solid tumor cancers, 2010-2019. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e13597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13597 Background: In recent years, efforts to improve the efficiency and speed of drug development and approval have driven a surge of Food and Drug Administration (FDA) approvals for cancer drugs. For many cancer therapies, the serious or life-threatening nature of the condition and unmet medical need confers eligibility for expedited programs. Many cancers are also rare diseases, and the increasing use of precision medicine principles to define cancer types further contributes to smaller trial sizes. With limited clinical evidence at the time of approval, cancer drugs may be subject to a greater burden of postmarketing requirements (PMRs). We analyzed PMRs for solid tumor therapies approved by the FDA over the past decade. Methods: The FDA’s novel drug approvals (2010-2019) were reviewed to identify drugs receiving primary approval for solid tumor indications. Approval letters were accessed via the Drugs@FDA database and analyzed for PMRs required under accelerated approval (AA), the Pediatric Research Equity Act (PREA) and the FDA Amendments Act of 2007 Section 505(o) (505(o)). Data are presented using descriptive statistics. Results: A total of 60 drugs received primary approval from the FDA for solid tumor indications between 2010 and 2019 (20 [33.3%] received AA, 33 [55.0%] received orphan designation, and 45 [75.0%] received Fast Track or Breakthrough Therapy designation). The proportion of drugs receiving AA doubled between the period 2010-2014 and 2015-2019 (Table). Of the 60 drugs approved, 52 (86.7%) received a total of 180 PMRs. All 20 drugs approved under AA received PMRs, with a total of 25 PMRs issued under AA. Data from new clinical trials were required for 22 (88.0%) of the 25 PMRs. No PMRs were issued under PREA. Additional safety data required under 505(o) comprised the largest proportion of PMRs; 155 total PMRs (86.1% of all PMRs) were issued for 45 (75.0%) of the drug approvals. Pharmacokinetic or other clinical safety data were required for 96 (61.9%) of the 155 PMRs. Conclusions: More than three-quarters of the cancer drugs approved for the treatment of solid tumors in the past 10 years were issued PMRs, with the majority requiring new safety data. The results of this study indicate that PMRs represent a critical mechanism by which FDA collects safety and efficacy for solid tumor therapies, and underscore the importance of PMR fulfillment. Post-marketing requirements (PMRs) for solid tumor drugs approved 2010-2019.[Table: see text]
Collapse
|
14
|
Mougalian SS, Zhang J, Kish J, Zettler ME, Feinberg BA. Real-world clinical effectiveness of eribulin in metastatic breast cancer patients with visceral metastases in the United States. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e13058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13058 Background: Eribulin mesylate was approved in the United States (US) in 2010 for the treatment of metastatic breast cancer (mBC) after at least two prior chemotherapeutic regimens, which should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. Visceral metastases, including those to the lung and brain, have been identified as poor prognostic features for patients with mBC. The objective of this analysis was to assess the real-world clinical effectiveness of eribulin in mBC patients with visceral metastases when treated in accordance with the US label. Methods: Patients with mBC initiating eribulin consistent with the US label between 2011-2017 were identified through a retrospective, multi-site chart review study conducted in US oncology practices. De-identified, patient-level demographics, clinical characteristics, treatment patterns, and outcomes were entered into an electronic case report form by the patients’ treating physicians. Sites of metastases at initiation of eribulin were indicated by providers. Clinical outcomes assessed included best overall response to eribulin as recorded in the patient’s chart, progression-free survival (PFS), and overall survival (OS). The proportion of patients with either a complete or partial response as their best overall response was calculated. PFS and OS were calculated by the Kaplan-Meier method from the initiation of eribulin for all patients with visceral metastases and subsets reporting lung or brain metastases site, respectively. Results: The analysis included 470 patients with visceral metastases, including 342 with lung metastases and 22 with brain metastases at the time of eribulin initiation. Eribulin was third-line therapy for approximately three quarters of patients in these subgroups, and the remainder received eribulin in fourth line or later. Mean age was 59 years in general (59 and 54 years in those with lung and brain metastases, respectively). Over half of patients (53.6%) had either a complete or partial response to eribulin. Median PFS was estimated at 6.0 months, and median OS was estimated at 10.5 months. Results for the subgroups of patients with lung and brain metastases are shown in the table. Conclusions: The results of this retrospective analysis affirm clinical effectiveness of eribulin in mBC patients with visceral metastases, when used consistent with the US label.[Table: see text]
Collapse
|
15
|
Zettler ME, Jeune-Smith Y, Feinberg BA, Phillips EG, Gajra A. Expanded Access and Right To Try Requests: The Community Oncologist's Experience. JCO Oncol Pract 2021; 17:e1719-e1727. [PMID: 33886355 PMCID: PMC8600511 DOI: 10.1200/op.20.00569] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE: For patients with cancer who have exhausted approved treatment options and for whom appropriate clinical trials are not available, access to investigational drugs through the US Food and Drug Administration's Expanded Access (EA) program has been an alternative since the program's inception more than 30 years ago. In 2018, federal Right To Try legislation was passed in the United States, creating a second pathway—one that bypasses the US Food and Drug Administration—to obtain unapproved drugs outside of clinical trials. The use of the two programs by community medical oncologists and hematologist-oncologists has not been studied. METHODS: Between October 2019 and February 2020, community oncologists-hematologists from across the United States completed web-based surveys about EA and Right To Try pathways for accessing unapproved drugs for their patients. Physicians were asked about their utilization of, and perceptions of, the two programs. RESULTS: Of the 238 physicians who completed the survey, 46% indicated that they had attempted to gain access to an investigational drug for a patient using the EA program, whereas 14% reported attempting to use Right To Try pathway to obtain an unapproved drug for a patient. Eighty-nine percent of those who tried to use the EA program reported success in obtaining the investigational drug versus 73% of those who attempted to use the Right To Try pathway. CONCLUSION: Our survey found that most community oncologists-hematologists were aware of both the EA and Right To Try pathways, but there is room for improvement in understanding and utilization of the programs.
Collapse
Affiliation(s)
| | | | - Bruce A Feinberg
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH
| | - Eli G Phillips
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH
| | - Ajeet Gajra
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH
| |
Collapse
|
16
|
Feinberg BA, Zettler ME, Klink AJ, Lee CH, Gajra A, Kish JK. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials. JAMA Netw Open 2021; 4:e2036741. [PMID: 33630085 PMCID: PMC7907955 DOI: 10.1001/jamanetworkopen.2020.36741] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
IMPORTANCE In clinical trials supporting the regulatory approval of oncology drugs, solid tumor response is assessed using Response Evaluation Criteria in Solid Tumors (RECIST). Calculation of RECIST-based responses requires sequential, timed imaging data, which presents challenges to the method's application in real-world evidence research. OBJECTIVE To evaluate the feasibility and validity of a novel real-world RECIST method in assessing tumor burden associated with therapy for a large heterogeneous patient population undergoing treatment in routine clinical practice. DESIGN, SETTING, AND PARTICIPANTS This cohort study used physician-abstracted data pooled from retrospective, multisite electronic health record (EHR) review studies of patients treated with anticancer drugs at US oncology practices from 2014 through 2017. Included patients were receiving first-line treatment for thyroid cancer, breast cancer, or metastatic melanoma. Data were analyzed from March through August 2020. EXPOSURES Undergoing treatment with immunotherapy or targeted therapy. MAIN OUTCOMES AND MEASURES Tumor response was classified according to RECIST guidelines (ie, change in sum diameter of target lesions) post hoc with measurements derived from imaging scans and reports. RESULTS Among 1308 completed electronic case report forms, 956 forms (73.1%) had adequate data to classify real-world RECIST response. The greatest difference between physician-recorded responses and real-world RECIST-based responses was found in the proportion of complete responses: 118 responses (12.3%) vs 46 responses (4.8%) (P < .001). Among 609 patients in the metastatic melanoma population, complete responses were reported in 112 physician-recorded responses (18.4%) vs 44 real-world RECIST-based responses (7.2%) (P < .001), compared with 11 of 247 responses (4.5%) to 31 of 192 responses (16.1%) across pivotal trials of the same melanoma therapies. CONCLUSIONS AND RELEVANCE These findings suggest that comparing tumor lesion sizes and categorizing treatment response according to RECIST guidelines may be feasible using real-world data. This study found that physician-recorded assessments were associated with overestimation of treatment response, with the largest overestimation among complete responses. Real-world RECIST-based assessments were associated with better approximations of tumor response reported in clinical trials compared with those reported in EHRs.
Collapse
Affiliation(s)
| | | | | | - Choo H Lee
- Cardinal Health Specialty Solutions, Dublin, Ohio
| | - Ajeet Gajra
- Cardinal Health Specialty Solutions, Dublin, Ohio
| | | |
Collapse
|
17
|
Feinberg BA, Gajra A, Zettler ME, Phillips TD, Phillips EG, Kish JK. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs. Value Health 2020; 23:1358-1365. [PMID: 33032780 DOI: 10.1016/j.jval.2020.06.006] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Revised: 06/11/2020] [Accepted: 06/19/2020] [Indexed: 05/02/2023]
Abstract
OBJECTIVES Real-world evidence (RWE) has gained increased attention in recent years as a complement to traditional clinical trials. The use of RWE to establish the efficacy of oncology drugs for Food and Drug Administration (FDA) approval has not been described. In this paper, we review 5 recent examples where RWE was submitted in support of the FDA approvals of original or supplementary indications for oncology drugs. METHODS To identify cases where RWE was used, we reviewed drug approval packages available at Drugs@FDA for oncology drugs approved between 2017 and 2019. Five cases were selected to present a broad overview of different types of RWE, different circumstances under which RWE has been used for regulatory approvals, and how FDA evaluated the data in each case. The type of RWE submitted, the indication, limitations identified by FDA reviewers, and the outcome of the submission are discussed. RESULTS RWE, particularly historical controls for rare or orphan indications, has been used to support both original and supplementary oncology drug approvals. Types of RWE included data from electronic health records, claims, post-marketing safety reports, retrospective medical record reviews, and expanded access studies. Small sample sizes, data quality, and methodological issues were among concerns cited by FDA reviewers. CONCLUSION By bridging the gap between the constraints of the trial setting and the realities of clinical practice, RWE can add value to a regulatory submission. These early examples provide insight into how regulators evaluated RWE submitted as evidence of efficacy for oncology drugs.
Collapse
Affiliation(s)
- Bruce A Feinberg
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH, USA.
| | - Ajeet Gajra
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH, USA
| | | | - Todd D Phillips
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH, USA
| | - Eli G Phillips
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH, USA
| | - Jonathan K Kish
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH, USA
| |
Collapse
|
18
|
Gajra A, Zettler ME, Phillips Jr EG, Klink AJ, Jonathan K Kish, Fortier S, Mehta S, Feinberg BA. Neurological adverse events following CAR T-cell therapy: a real-world analysis. Immunotherapy 2020; 12:1077-1082. [DOI: 10.2217/imt-2020-0161] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Aim: To characterize real-world neurological adverse events (AEs) associated with chimeric antigen receptor T-cell therapies in patients with refractory/relapsed large B-cell lymphomas. Materials & methods: Postmarketing case reports from the US FDA AEs reporting system involving axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for large B-cell lymphomas were analyzed. Results: Of 804 AE cases identified (637 axi-cel, 167 tisa-cel), 428 (67%) of axi-cel cases and 43 (26%) of tisa-cel cases reported neurological AEs. Compared with cases without neurological AEs, significant associations were observed between neurological AEs and use of axi-cel, age ≥65 years, and the outcome of hospitalization. Conclusion: Neurological AEs were common with chimeric antigen receptor T-cell therapy in the real world and largely reflected those reported in clinical trials.
Collapse
Affiliation(s)
- Ajeet Gajra
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH 43017, USA
| | - Marjorie E Zettler
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH 43017, USA
| | - Eli G Phillips Jr
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH 43017, USA
| | - Andrew J Klink
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH 43017, USA
| | - Jonathan K Kish
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH 43017, USA
| | - Stephanie Fortier
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH 43017, USA
| | - Sonam Mehta
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH 43017, USA
| | - Bruce A Feinberg
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH 43017, USA
| |
Collapse
|
19
|
Zettler ME, Feinberg BA, Phillips EG, Klink AJ, Mehta S, Gajra A. Real-world adverse events associated with CAR T-cell therapy among adults age ≥ 65 years. J Geriatr Oncol 2020; 12:239-242. [PMID: 32798213 DOI: 10.1016/j.jgo.2020.07.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Revised: 05/22/2020] [Accepted: 07/06/2020] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for relapsed or refractory large B-cell lymphoma (LBCL) with the Food and Drug Administration (FDA) approvals of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tis-cel). Although the incidence of LBCL is highest among patients age ≥ 65, clinical trials supporting approval of these 2 products primarily enrolled younger patients. Safety data for axi-cel and tis-cel in older patients is limited. METHODS In this analysis, we queried the FDA Adverse Events Reporting System (FAERS) database for cases associated with axi-cel or tis-cel from the FDA approval dates for the LBCL indication for each product through December 31, 2019, and compared adverse events (AEs) reported for cases involving patients aged <65 and ≥ 65. RESULTS A total of 804 cases were retrieved, with 333 (41%) involving patients age ≥ 65. Cytokine release syndrome (CRS) was the most common AE reported in both age groups. Cases involving older patients had a significantly higher proportion of neurological AEs, including CAR T-cell-related encephalopathy syndrome (8% vs. 4%, p = 0.03). Some individual clinical features of CRS were significantly more common among younger age group cases, including pyrexia (33% vs. 23%, p < 0.01), tachycardia (10% vs. 5%, p < 0.01), and thrombocytopenia (4% vs. 2%, p = 0.03). DISCUSSION In this age-based analysis of FAERS reports for patients treated with axi-cel or tis-cel, we identified differences in patterns of AEs experienced. This large-scale post-marketing study complements clinical trial safety data and may help inform clinicians' decision making when treating adult patients with CAR-T cell therapy.
Collapse
Affiliation(s)
- Marjorie E Zettler
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH, United States of America
| | - Bruce A Feinberg
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH, United States of America
| | - Eli G Phillips
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH, United States of America
| | - Andrew J Klink
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH, United States of America
| | - Sonam Mehta
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH, United States of America
| | - Ajeet Gajra
- Cardinal Health Specialty Solutions, Cardinal Health, Dublin, OH, United States of America.
| |
Collapse
|
20
|
Fosbøl EL, Ju C, Anstrom KJ, Zettler ME, Messenger JC, Waksman R, Effron MB, Baker BA, Cohen DJ, Peterson ED, Wang TY. Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome). Circ Cardiovasc Interv 2017; 9:CIRCINTERVENTIONS.115.003602. [PMID: 27789517 DOI: 10.1161/circinterventions.115.003602] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Accepted: 09/26/2016] [Indexed: 11/16/2022]
Abstract
BACKGROUND Guidelines recommend the use of adenosine diphosphate receptor inhibitor (ADPri) therapy for 1 year postacute myocardial infarction; yet, early cessation of therapy occurs frequently in clinical practice. METHODS AND RESULTS We examined 11 858 acute myocardial infarction patients treated with percutaneous coronary intervention discharged alive on ADPri therapy from 233 United States TRANSLATE-ACS study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) participating hospitals to determine the prevalence of early ADPri cessation (within 1 year), patient-reported reasons for cessation, and associated risk of major adverse cardiovascular events at 1 year. Overall, 2514 (21.2%) of percutaneous coronary intervention-treated patients stopped ADPri by 1 year postmyocardial infarction; the median time from discharge to cessation was 200.5 days (25th, 75th percentiles: 71, 340). Among those with early ADPri cessation, 53.9% received drug-eluting stents and had a median duration of 301 treatment days (25th, 75th percentiles: 137, 353); 33.3% of drug-eluting stent patients stopped treatment within 6 months compared with 64.2% of bare metal stent patients. Those discharged on prasugrel (versus clopidogrel) had a slightly higher likelihood of early ADPri cessation (23.2% versus 21.0%; P=0.03; adjusted hazard ratio, 1.28; 95% confidence interval, 1.17-1.40). Patient-reported reasons for early ADPri cessation included physician-recommended discontinuation (54%), as well as patient self-discontinuation, because of cost (19%), medication side effects (9%), and procedural interruption (10%). Using a time-dependent covariate model, early cessation of ADPri therapy was associated with increased major adverse cardiovascular event (adjusted hazard ratio, 1.40; 95% confidence interval, 1.19-1.65; P<0.0001). CONCLUSIONS One in 5 percutaneous coronary intervention-treated myocardial infarction patients stopped ADPri treatment within 1 year. Early cessation was associated with increased major adverse cardiovascular event risk. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01088503.
Collapse
Affiliation(s)
- Emil L Fosbøl
- From The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark (E.L.F.); Duke Clinical Research Institute, Durham, NC (E.L.F., C.J., K.J.A., E.D.P., T.Y.W.); The Danish Heart Foundation, Copenhagen, Denmark (E.L.F.); Eli Lilly and Company, Indianapolis, IN (M.E.Z., M.B.E.); University of Colorado School of Medicine, Aurora (J.C.M.); Cardiovascular Research Institute, MedStar Washington Hospital Center, Washington, DC (R.W.); John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA (M.B.E.); Daiichi Sankyo, Inc., Parsippany, NJ (B.A.B.); and Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.).
| | - Christine Ju
- From The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark (E.L.F.); Duke Clinical Research Institute, Durham, NC (E.L.F., C.J., K.J.A., E.D.P., T.Y.W.); The Danish Heart Foundation, Copenhagen, Denmark (E.L.F.); Eli Lilly and Company, Indianapolis, IN (M.E.Z., M.B.E.); University of Colorado School of Medicine, Aurora (J.C.M.); Cardiovascular Research Institute, MedStar Washington Hospital Center, Washington, DC (R.W.); John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA (M.B.E.); Daiichi Sankyo, Inc., Parsippany, NJ (B.A.B.); and Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.)
| | - Kevin J Anstrom
- From The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark (E.L.F.); Duke Clinical Research Institute, Durham, NC (E.L.F., C.J., K.J.A., E.D.P., T.Y.W.); The Danish Heart Foundation, Copenhagen, Denmark (E.L.F.); Eli Lilly and Company, Indianapolis, IN (M.E.Z., M.B.E.); University of Colorado School of Medicine, Aurora (J.C.M.); Cardiovascular Research Institute, MedStar Washington Hospital Center, Washington, DC (R.W.); John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA (M.B.E.); Daiichi Sankyo, Inc., Parsippany, NJ (B.A.B.); and Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.)
| | - Marjorie E Zettler
- From The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark (E.L.F.); Duke Clinical Research Institute, Durham, NC (E.L.F., C.J., K.J.A., E.D.P., T.Y.W.); The Danish Heart Foundation, Copenhagen, Denmark (E.L.F.); Eli Lilly and Company, Indianapolis, IN (M.E.Z., M.B.E.); University of Colorado School of Medicine, Aurora (J.C.M.); Cardiovascular Research Institute, MedStar Washington Hospital Center, Washington, DC (R.W.); John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA (M.B.E.); Daiichi Sankyo, Inc., Parsippany, NJ (B.A.B.); and Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.)
| | - John C Messenger
- From The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark (E.L.F.); Duke Clinical Research Institute, Durham, NC (E.L.F., C.J., K.J.A., E.D.P., T.Y.W.); The Danish Heart Foundation, Copenhagen, Denmark (E.L.F.); Eli Lilly and Company, Indianapolis, IN (M.E.Z., M.B.E.); University of Colorado School of Medicine, Aurora (J.C.M.); Cardiovascular Research Institute, MedStar Washington Hospital Center, Washington, DC (R.W.); John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA (M.B.E.); Daiichi Sankyo, Inc., Parsippany, NJ (B.A.B.); and Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.)
| | - Ron Waksman
- From The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark (E.L.F.); Duke Clinical Research Institute, Durham, NC (E.L.F., C.J., K.J.A., E.D.P., T.Y.W.); The Danish Heart Foundation, Copenhagen, Denmark (E.L.F.); Eli Lilly and Company, Indianapolis, IN (M.E.Z., M.B.E.); University of Colorado School of Medicine, Aurora (J.C.M.); Cardiovascular Research Institute, MedStar Washington Hospital Center, Washington, DC (R.W.); John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA (M.B.E.); Daiichi Sankyo, Inc., Parsippany, NJ (B.A.B.); and Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.)
| | - Mark B Effron
- From The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark (E.L.F.); Duke Clinical Research Institute, Durham, NC (E.L.F., C.J., K.J.A., E.D.P., T.Y.W.); The Danish Heart Foundation, Copenhagen, Denmark (E.L.F.); Eli Lilly and Company, Indianapolis, IN (M.E.Z., M.B.E.); University of Colorado School of Medicine, Aurora (J.C.M.); Cardiovascular Research Institute, MedStar Washington Hospital Center, Washington, DC (R.W.); John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA (M.B.E.); Daiichi Sankyo, Inc., Parsippany, NJ (B.A.B.); and Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.)
| | - Brian A Baker
- From The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark (E.L.F.); Duke Clinical Research Institute, Durham, NC (E.L.F., C.J., K.J.A., E.D.P., T.Y.W.); The Danish Heart Foundation, Copenhagen, Denmark (E.L.F.); Eli Lilly and Company, Indianapolis, IN (M.E.Z., M.B.E.); University of Colorado School of Medicine, Aurora (J.C.M.); Cardiovascular Research Institute, MedStar Washington Hospital Center, Washington, DC (R.W.); John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA (M.B.E.); Daiichi Sankyo, Inc., Parsippany, NJ (B.A.B.); and Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.)
| | - David J Cohen
- From The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark (E.L.F.); Duke Clinical Research Institute, Durham, NC (E.L.F., C.J., K.J.A., E.D.P., T.Y.W.); The Danish Heart Foundation, Copenhagen, Denmark (E.L.F.); Eli Lilly and Company, Indianapolis, IN (M.E.Z., M.B.E.); University of Colorado School of Medicine, Aurora (J.C.M.); Cardiovascular Research Institute, MedStar Washington Hospital Center, Washington, DC (R.W.); John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA (M.B.E.); Daiichi Sankyo, Inc., Parsippany, NJ (B.A.B.); and Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.)
| | - Eric D Peterson
- From The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark (E.L.F.); Duke Clinical Research Institute, Durham, NC (E.L.F., C.J., K.J.A., E.D.P., T.Y.W.); The Danish Heart Foundation, Copenhagen, Denmark (E.L.F.); Eli Lilly and Company, Indianapolis, IN (M.E.Z., M.B.E.); University of Colorado School of Medicine, Aurora (J.C.M.); Cardiovascular Research Institute, MedStar Washington Hospital Center, Washington, DC (R.W.); John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA (M.B.E.); Daiichi Sankyo, Inc., Parsippany, NJ (B.A.B.); and Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.)
| | - Tracy Y Wang
- From The Heart Centre, University Hospital of Copenhagen, Rigshospitalet, Denmark (E.L.F.); Duke Clinical Research Institute, Durham, NC (E.L.F., C.J., K.J.A., E.D.P., T.Y.W.); The Danish Heart Foundation, Copenhagen, Denmark (E.L.F.); Eli Lilly and Company, Indianapolis, IN (M.E.Z., M.B.E.); University of Colorado School of Medicine, Aurora (J.C.M.); Cardiovascular Research Institute, MedStar Washington Hospital Center, Washington, DC (R.W.); John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA (M.B.E.); Daiichi Sankyo, Inc., Parsippany, NJ (B.A.B.); and Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.)
| |
Collapse
|
21
|
Effron MB, Wang TY, Fonarow GC, Henry TD, Zettler ME, Baker BA, McCoy LA, Peterson ED. The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study. Catheter Cardiovasc Interv 2017; 91:242-250. [DOI: 10.1002/ccd.27145] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Revised: 03/30/2017] [Accepted: 04/29/2017] [Indexed: 11/08/2022]
Affiliation(s)
- Mark B. Effron
- US Medical Affairs-Cardiovascular; Eli Lilly and Company; Indianapolis Indiana
- Department of Cardiology; John Ochsner Heart and Vascular Institute, Ochsner Medical Center; New Orleans Louisiana
| | - Tracy Y. Wang
- Duke Clinical Research Institute; Durham North Carolina
| | - Gregg C. Fonarow
- Division of Cardiology; Ronald Reagan UCLA Medical Center; Los Angeles California
| | - Timothy D. Henry
- Division of Cardiology; Cedars-Sinai Medical Center; Los Angeles California
- Division of Cardiology; Minneapolis Heart Institute; Minneapolis Minnesota
| | - Marjorie E. Zettler
- US Medical Affairs-Cardiovascular; Eli Lilly and Company; Indianapolis Indiana
| | | | - Lisa A. McCoy
- Duke Clinical Research Institute; Durham North Carolina
| | | |
Collapse
|
22
|
Ibrahim H, Sharma PK, Cohen DJ, Fonarow GC, Kaltenbach LA, Effron MB, Zettler ME, Peterson ED, Wang TY. Multivessel Versus Culprit Vessel-Only Percutaneous Coronary Intervention Among Patients With Acute Myocardial Infarction: Insights From the TRANSLATE-ACS Observational Study. J Am Heart Assoc 2017; 6:JAHA.117.006343. [PMID: 28982673 PMCID: PMC5721846 DOI: 10.1161/jaha.117.006343] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Background Among patients with acute myocardial infarction (MI) who have multivessel disease, it is unclear if multivessel percutaneous coronary intervention (PCI) improves clinical and quality‐of‐life outcomes compared with culprit‐only intervention. We sought to compare clinical and quality‐of‐life outcomes between multivessel and culprit‐only PCI. Methods and Results Among 6061 patients with acute MI who have multivessel disease in the TRANSLATE‐ACS (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) study, we used inverse probability‐weighted propensity adjustment to study the associations between multivessel and culprit‐only intervention during the index PCI and major adverse cardiovascular events, unplanned all‐cause readmission, and angina frequency at 6 weeks and 1 year. Multivessel PCI was performed in 1208 (20%) of patients with MI who had multivessel disease. Relative to the culprit‐only intervention, patients receiving multivessel PCI were similarly aged and more likely to be seen with non–ST‐segment elevation MI or cardiogenic shock. At 6 weeks, the initial multivessel PCI strategy was associated with lower major adverse cardiovascular events and unplanned readmission risks, whereas angina frequency was not significantly different between multivessel and culprit‐only PCI. At 1 year, major adverse cardiovascular event risk was persistently lower in the multivessel PCI group (adjusted hazard ratio, 0.84; 95% confidence interval, 0.72–0.99), whereas long‐term readmission risk (adjusted hazard ratio, 0.94; 95% confidence interval, 0.84–1.04) and angina frequency were similar between groups (adjusted odds ratio, 1.01; 95% confidence interval, 0.82–1.24). Similar associations were seen when patients with ST‐segment elevation MI and non–ST‐segment elevation MI were examined separately. Conclusions Among patients with acute MI who have multivessel disease, multivessel PCI was associated with lower risk of all‐cause readmission at 6 weeks and lower risk of major adverse cardiovascular events at 6 weeks and 1 year. However, similar short‐ and long‐term angina frequencies were noted.
Collapse
Affiliation(s)
- Homam Ibrahim
- University of Utah Cardiovascular division, Salt Lake City, UT
| | | | - David J Cohen
- Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City School of Medicine, Kansas City, MO
| | | | | | - Mark B Effron
- Lilly USA, LLC, Indianapolis, IN.,John Ochsner Heart and Vascular Institute Ochsner Medical Center, New Orleans, LA
| | | | | | | |
Collapse
|
23
|
Bagai A, Peterson ED, McCoy LA, Effron MB, Zettler ME, Stone GW, Henry TD, Cohen DJ, Schulte PJ, Anstrom KJ, Wang TY. Association of measured platelet reactivity with changes in P2Y 12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. Am Heart J 2017; 187:19-28. [PMID: 28454802 DOI: 10.1016/j.ahj.2017.02.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2016] [Accepted: 02/07/2017] [Indexed: 10/20/2022]
Abstract
BACKGROUND Little is known about the use of platelet function testing to guide choice of P2Y12 receptor inhibitor therapy in routine clinical practice. METHODS We studied 671 myocardial infarction (MI) patients treated with percutaneous coronary intervention in the TRANSLATE-ACS Registry who had VerifyNow platelet function testing performed while on clopidogrel treatment during their index hospitalization (April 2010-October 2012). RESULTS High platelet reactivity (>208 platelet reactivity units [PRU]) was present in 261 (38.9%) patients. Clopidogrel was switched in-hospital to prasugrel in 80 (30.7%) patients with high platelet reactivity and 18 (4.4%) patients with therapeutic platelet reactivity (≤208 PRU). Among high platelet reactivity patients, switch to prasugrel was associated with lower major adverse cardiovascular events (death, MI, stroke, or unplanned revascularization) at 1year (10.0% vs 22.7%, P=.02; adjusted odds ratio [OR] 0.39, 95% CI 0.18-0.85, P=.02) and no significant difference in Bleeding Academic Research Consortium type 2 or higher bleeding (23.8% vs 22.1%, P=.77; adjusted OR 0.91, 95% CI 0.48-1.7, P=.77) compared with patients continued on clopidogrel. No significant differences in major adverse cardiovascular event (22.2% vs 12.8%, P=.25; adjusted OR 1.8, 95% CI 0.47-7.3, P=.38) or bleeding (22.2% vs 19.4%, P=.77; adjusted OR 1.3, 95% CI 0.27-6.8, P=.72) were observed among therapeutic platelet reactivity patients between switching and continuation on clopidogrel. CONCLUSIONS Only one-third of percutaneous coronary intervention-treated MI patients with high on-clopidogrel platelet reactivity were switched to a more potent P2Y12 receptor inhibitor. Intensification of antiplatelet therapy was associated with lower risk of ischemic events at 1year among HPR patients.
Collapse
|
24
|
Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, Baker BA, Messenger JC, Cohen DJ, Wang TY. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J 2017; 183:62-68. [PMID: 27979043 DOI: 10.1016/j.ahj.2016.10.006] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Accepted: 10/07/2016] [Indexed: 11/28/2022]
Abstract
The reasons for postdischarge adenosine diphosphate receptor inhibitor (ADPri) switching among patients with myocardial infarction (MI) are unclear. We sought to describe the incidence and patterns of postdischarge ADPri switching among patients with acute MI treated with percutaneous coronary intervention. METHODS We used TRANSLATE-ACS (2010-2012) data to assess postdischarge ADPri switching among 8,672 MI patients discharged after percutaneous coronary intervention who remained on ADPri therapy 1 year post-MI. We examined patient-reported reasons for switching, GUSTO moderate or severe bleeding, major adverse cardiovascular events (MACEs), and definite stent thrombosis events around the time of the switch. RESULTS Among patients still on ADPri therapy 1 year post-MI, 663 (7.6%) switched ADPri during that year. Switching occurred at a median of 50 days postdischarge and most frequently in patients discharged on ticagrelor (64/226; 28.3%), followed by prasugrel (383/2,489; 15.4%) and clopidogrel (216/5,957; 3.6%) (P < .001). Among patients discharged on prasugrel, 97.3% of switches were to clopidogrel and 87.5% of ticagrelor switches were to clopidogrel; both of these groups most often cited cost as a reason for switching (43.6% and 39.1%, respectively), whereas 60.7% who switched from clopidogrel cited physician decision as a reason. In the 7 days preceding the switch from clopidogrel, 40 (18.5%) had a MACE and 12 (5.6%) had a definite stent thrombosis event, whereas that from prasugrel or ticagrelor, a GUSTO moderate or severe bleeding event occurred in 1 (0.3%) and 0 patients, respectively. CONCLUSIONS Postdischarge ADPri switching occurred infrequently within the first year post-MI and uncommonly was associated with MACEs or bleeding events.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - David J Cohen
- Saint Luke's Mid America Heart Institute, Kansas City, MO
| | | |
Collapse
|
25
|
Vora AN, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Faries DE, Zettler ME, Fonarow GC, Baker BA, Stone GW, Wang TY. Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. J Am Heart Assoc 2016; 5:JAHA.116.003946. [PMID: 27663414 PMCID: PMC5079042 DOI: 10.1161/jaha.116.003946] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Background Few studies have examined how antiplatelet therapies are selected during the routine care of acute myocardial infarction patients, particularly relative to the patient's estimated mortality and bleeding risks. Methods and Results We examined patients presenting with acute myocardial infarction treated with percutaneous coronary intervention at 233 US hospitals in the TRANSLATE‐ACS observational study from April 2010 to October 2012. We developed a multivariable logistic regression model to identify factors associated with prasugrel selection. Prasugrel use rates and associated 1‐year risk‐adjusted major adverse cardiovascular events and Global Utilization of Streptokinase and t‐PA for Occluded Coronary Arteries (GUSTO) moderate/severe bleeding outcomes were also examined in relation to predicted mortality and bleeding using the validated Acute Coronary Treatment and Intervention Outcomes (ACTION) risk prediction scores. Among 11 969 patients, 3123 (26%) received prasugrel at the time of percutaneous coronary intervention. The strongest factors associated with prasugrel use included cardiogenic shock (odds ratio [OR] 1.68, 95% CI 1.25–2.26), drug‐eluting stent use (OR 1.45, 95% CI 1.31–1.62), and ST‐segment elevation myocardial infarction presentation (OR 1.23, 95% CI 1.12–1.35). Older age (OR 0.57, 95% CI 0.0.53–0.61), dialysis (OR 0.56, 95% CI 0.32–0.96), prior history of stroke/transient ischemic attack (OR 0.52, 95% CI 0.38–0.73), and interhospital transfer (OR 0.50, 95% CI 0.46–0.55) were associated with lowest prasugrel selection. Prasugrel was used less often than clopidogrel in patients at higher predicted bleeding risk (21.9% versus 29.7%, P<0.001). Yet paradoxically, prasugrel was also less likely than clopidogrel to be used in patients with higher predicted mortality risk (21.1% versus 30.2%, P<0.001). Adjusted bleeding and outcomes events were similar among those receiving prasugrel and clopidogrel in the 4 subgroups of patients based on bleeding risk and ischemic benefits. Conclusions In community practice, prasugrel use may be driven more by bleeding risk rather than ischemic benefit. This may result in underutilization of higher potency ADP receptor inhibitor among patients more likely to derive ischemic benefit.
Collapse
Affiliation(s)
- Amit N Vora
- Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
| | - Eric D Peterson
- Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
| | - Lisa A McCoy
- Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
| | | | - Kevin J Anstrom
- Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
| | | | | | - Gregg C Fonarow
- Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles, CA
| | | | - Gregg W Stone
- Columbia University College of Physicians and Surgeons, New York, NY
| | - Tracy Y Wang
- Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
| |
Collapse
|
26
|
Wang TY, Henry TD, Effron MB, Honeycutt E, Hess CN, Zettler ME, Cohen DJ, Baker BA, Berger PB, Anstrom KJ, Angiolillo DJ, Peterson ED. Cluster-randomized clinical trial examining the impact of platelet function testing on practice: the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study. Circ Cardiovasc Interv 2016; 8:e001712. [PMID: 26025216 DOI: 10.1161/circinterventions.114.001712] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Little is known about how clinicians use platelet function testing to guide choice and dosing of adenosine diphosphate receptor inhibitor (ADPri) therapy in routine community practice. METHODS AND RESULTS The Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (ACS)-Prospective, Open Label, Antiplatelet Therapy Study (TRANSLATE-POPS) was a cluster-randomized trial in which 100 hospitals were assigned access to no-cost platelet function testing versus usual care for acute myocardial infarction patients treated with percutaneous coronary intervention. In both arms, ADPri treatment decisions were left up to the care team. The primary end point was the frequency of ADPri therapy adjustment before discharge. Secondary end points included 30-day rates of major adverse cardiovascular events and Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries-defined bleeding events. Platelet function testing was performed in 66.9% of patients treated in intervention sites versus 1.4% of patients in usual care sites. Intervention arm patients were more likely to have ADPri therapy adjustment than usual care patients (14.8% versus 10.5%, P=0.004; odds ratio 1.68, 95% confidence interval 1.18-2.40); however, there were no significant differences in 30-day major adverse cardiovascular events (4.8% versus 5.4%, P=0.73; odds ratio 0.94, 95% confidence interval 0.66-1.34) or bleeding (4.3% versus 4.2%, P=0.33; odds ratio 0.86, 95% confidence interval 0.55-1.34). One-year outcomes were also not significantly different between groups. An as-treated analysis showed higher incidence of ADPri therapy adjustment among intervention arm patients who received platelet function testing than untested usual care arm (16.4% versus 10.2%, P<0.0001), but no significant differences in major adverse cardiovascular events or bleeding. CONCLUSIONS TRANSLATE-POPS found that when clinicians routinely used platelet function testing, they were more likely to adjust their choice or dosing of ADPri therapy; yet with few changes in therapy overall, significant differences in clinical outcomes were not seen. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01088503.
Collapse
Affiliation(s)
- Tracy Y Wang
- From the Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC (T.Y.W., E.H., C.N.H., K.J.A., E.D.P.); Department of Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); Lilly USA, LLC, Indianapolis, IN (M.B.E., M.E.Z.); Department of Medicine, Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.); Daiichi Sankyo, Inc, Parsippany, NJ (B.A.B.); Department of Medicine, Geisinger Medical Center, Danville, PA (P.B.B.); and Department of Medicine, University of Florida College of Medicine, Jacksonville, FL (D.J.A.).
| | - Timothy D Henry
- From the Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC (T.Y.W., E.H., C.N.H., K.J.A., E.D.P.); Department of Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); Lilly USA, LLC, Indianapolis, IN (M.B.E., M.E.Z.); Department of Medicine, Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.); Daiichi Sankyo, Inc, Parsippany, NJ (B.A.B.); Department of Medicine, Geisinger Medical Center, Danville, PA (P.B.B.); and Department of Medicine, University of Florida College of Medicine, Jacksonville, FL (D.J.A.)
| | - Mark B Effron
- From the Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC (T.Y.W., E.H., C.N.H., K.J.A., E.D.P.); Department of Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); Lilly USA, LLC, Indianapolis, IN (M.B.E., M.E.Z.); Department of Medicine, Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.); Daiichi Sankyo, Inc, Parsippany, NJ (B.A.B.); Department of Medicine, Geisinger Medical Center, Danville, PA (P.B.B.); and Department of Medicine, University of Florida College of Medicine, Jacksonville, FL (D.J.A.)
| | - Emily Honeycutt
- From the Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC (T.Y.W., E.H., C.N.H., K.J.A., E.D.P.); Department of Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); Lilly USA, LLC, Indianapolis, IN (M.B.E., M.E.Z.); Department of Medicine, Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.); Daiichi Sankyo, Inc, Parsippany, NJ (B.A.B.); Department of Medicine, Geisinger Medical Center, Danville, PA (P.B.B.); and Department of Medicine, University of Florida College of Medicine, Jacksonville, FL (D.J.A.)
| | - Connie N Hess
- From the Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC (T.Y.W., E.H., C.N.H., K.J.A., E.D.P.); Department of Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); Lilly USA, LLC, Indianapolis, IN (M.B.E., M.E.Z.); Department of Medicine, Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.); Daiichi Sankyo, Inc, Parsippany, NJ (B.A.B.); Department of Medicine, Geisinger Medical Center, Danville, PA (P.B.B.); and Department of Medicine, University of Florida College of Medicine, Jacksonville, FL (D.J.A.)
| | - Marjorie E Zettler
- From the Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC (T.Y.W., E.H., C.N.H., K.J.A., E.D.P.); Department of Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); Lilly USA, LLC, Indianapolis, IN (M.B.E., M.E.Z.); Department of Medicine, Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.); Daiichi Sankyo, Inc, Parsippany, NJ (B.A.B.); Department of Medicine, Geisinger Medical Center, Danville, PA (P.B.B.); and Department of Medicine, University of Florida College of Medicine, Jacksonville, FL (D.J.A.)
| | - David J Cohen
- From the Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC (T.Y.W., E.H., C.N.H., K.J.A., E.D.P.); Department of Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); Lilly USA, LLC, Indianapolis, IN (M.B.E., M.E.Z.); Department of Medicine, Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.); Daiichi Sankyo, Inc, Parsippany, NJ (B.A.B.); Department of Medicine, Geisinger Medical Center, Danville, PA (P.B.B.); and Department of Medicine, University of Florida College of Medicine, Jacksonville, FL (D.J.A.)
| | - Brian A Baker
- From the Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC (T.Y.W., E.H., C.N.H., K.J.A., E.D.P.); Department of Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); Lilly USA, LLC, Indianapolis, IN (M.B.E., M.E.Z.); Department of Medicine, Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.); Daiichi Sankyo, Inc, Parsippany, NJ (B.A.B.); Department of Medicine, Geisinger Medical Center, Danville, PA (P.B.B.); and Department of Medicine, University of Florida College of Medicine, Jacksonville, FL (D.J.A.)
| | - Peter B Berger
- From the Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC (T.Y.W., E.H., C.N.H., K.J.A., E.D.P.); Department of Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); Lilly USA, LLC, Indianapolis, IN (M.B.E., M.E.Z.); Department of Medicine, Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.); Daiichi Sankyo, Inc, Parsippany, NJ (B.A.B.); Department of Medicine, Geisinger Medical Center, Danville, PA (P.B.B.); and Department of Medicine, University of Florida College of Medicine, Jacksonville, FL (D.J.A.)
| | - Kevin J Anstrom
- From the Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC (T.Y.W., E.H., C.N.H., K.J.A., E.D.P.); Department of Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); Lilly USA, LLC, Indianapolis, IN (M.B.E., M.E.Z.); Department of Medicine, Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.); Daiichi Sankyo, Inc, Parsippany, NJ (B.A.B.); Department of Medicine, Geisinger Medical Center, Danville, PA (P.B.B.); and Department of Medicine, University of Florida College of Medicine, Jacksonville, FL (D.J.A.)
| | - Dominick J Angiolillo
- From the Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC (T.Y.W., E.H., C.N.H., K.J.A., E.D.P.); Department of Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); Lilly USA, LLC, Indianapolis, IN (M.B.E., M.E.Z.); Department of Medicine, Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.); Daiichi Sankyo, Inc, Parsippany, NJ (B.A.B.); Department of Medicine, Geisinger Medical Center, Danville, PA (P.B.B.); and Department of Medicine, University of Florida College of Medicine, Jacksonville, FL (D.J.A.)
| | - Eric D Peterson
- From the Duke Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC (T.Y.W., E.H., C.N.H., K.J.A., E.D.P.); Department of Medicine, Cedars-Sinai Heart Institute, Los Angeles, CA (T.D.H.); Lilly USA, LLC, Indianapolis, IN (M.B.E., M.E.Z.); Department of Medicine, Saint Luke's Mid America Heart Institute, Kansas City, MO (D.J.C.); Daiichi Sankyo, Inc, Parsippany, NJ (B.A.B.); Department of Medicine, Geisinger Medical Center, Danville, PA (P.B.B.); and Department of Medicine, University of Florida College of Medicine, Jacksonville, FL (D.J.A.)
| | | |
Collapse
|
27
|
Krishnamoorthy A, Peterson ED, Knight JD, Anstrom KJ, Effron MB, Zettler ME, Davidson-Ray L, Baker BA, McCollam PL, Mark DB, Wang TY. How Reliable are Patient-Reported Rehospitalizations? Implications for the Design of Future Practical Clinical Studies. J Am Heart Assoc 2016; 5:JAHA.115.002695. [PMID: 26811163 PMCID: PMC4859389 DOI: 10.1161/jaha.115.002695] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background Longitudinal clinical investigations often rely on patient reports to screen for postdischarge adverse outcomes events, yet few studies have examined the accuracy of such patient reports. Methods and Results Patients with acute myocardial infarction (MI) in the TRANSLATE‐ACS study were asked during structured interviews at 6 weeks, 6 months, and 12 months postdischarge to report any rehospitalizations. The accuracy of patient‐reported rehospitalizations within 1 year of postdischarge was determined using claims‐based medical bill validation as the reference standard. The cumulative incidence of rehospitalizations was compared when identified by patient report versus medical bills. Patients were categorized by the accuracy in reporting events (accurate, under‐, or over‐ reporters) and characteristics were compared between groups. Among 10 643 MI patients, 4565 (43%) reported 7734 rehospitalizations. The sensitivity and positive predictive value of patient‐reported rehospitalizations were low at 67% and 59%, respectively. A higher cumulative incidence of rehospitalization was observed when identified by patient report versus medical bills (43% vs 37%; P<0.001). Overall, 18% of patients over‐reported and 10% under‐reported the number of hospitalizations. Compared with accurate reporters, under‐reporters were more likely to be older, female, African American, unemployed, or a non‐high‐school graduate, and had greater prevalence of clinical comorbidities such as diabetes and past cardiovascular disease. Conclusions The accuracy of patient‐reported rehospitalizations was low with patients both under‐ and over‐reporting events. Longitudinal clinical research studies need additional mechanisms beyond patient report to accurately identify rehospitalization events. Clinical Trial Registration URL: https://clinicaltrials.gov. Unique identifier: NCT01088503.
Collapse
Affiliation(s)
- Arun Krishnamoorthy
- Duke Clinical Research Institute, Durham, NC (A.K., E.D.P., D.K., K.J.A., L.D.R., D.B.M., T.Y.W.)
| | - Eric D Peterson
- Duke Clinical Research Institute, Durham, NC (A.K., E.D.P., D.K., K.J.A., L.D.R., D.B.M., T.Y.W.)
| | - J David Knight
- Duke Clinical Research Institute, Durham, NC (A.K., E.D.P., D.K., K.J.A., L.D.R., D.B.M., T.Y.W.)
| | - Kevin J Anstrom
- Duke Clinical Research Institute, Durham, NC (A.K., E.D.P., D.K., K.J.A., L.D.R., D.B.M., T.Y.W.)
| | - Mark B Effron
- Eli Lilly & Company, Indianapolis, IN (M.B.E., M.E.Z., P.L.M.C.)
| | | | - Linda Davidson-Ray
- Duke Clinical Research Institute, Durham, NC (A.K., E.D.P., D.K., K.J.A., L.D.R., D.B.M., T.Y.W.)
| | | | | | - Daniel B Mark
- Duke Clinical Research Institute, Durham, NC (A.K., E.D.P., D.K., K.J.A., L.D.R., D.B.M., T.Y.W.)
| | - Tracy Y Wang
- Duke Clinical Research Institute, Durham, NC (A.K., E.D.P., D.K., K.J.A., L.D.R., D.B.M., T.Y.W.)
| |
Collapse
|
28
|
Hess CN, Wang TY, McCoy LA, Messenger JC, Effron MB, Zettler ME, Henry TD, Peterson ED, Fonarow GC. Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. Circulation 2015; 133:493-501. [PMID: 26680241 DOI: 10.1161/circulationaha.115.017001] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2015] [Accepted: 11/20/2015] [Indexed: 11/16/2022]
Abstract
BACKGROUND Previous studies examining early readmission after acute myocardial infarction have focused exclusively on inpatient readmissions. However, from a patient's perspective, any unplanned inpatient or observation rehospitalization after acute myocardial infarction represents a significant event; these unplanned rehospitalizations have not been well characterized. METHODS AND RESULTS We examined all patients with acute myocardial infarction treated with percutaneous coronary intervention and discharged alive from 233 hospitals in the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) study from 2010 to 2012. Our primary outcome was unplanned rehospitalizations (inpatient or observation status) within 30 days after discharge. We identified factors associated with unplanned rehospitalizations using multivariable logistic regression. Among 12 312 patients, 1326 (10.8%) had 1483 unplanned rehospitalizations within 30 days of the index event: 1028 (69.3%) were inpatient readmissions, and 455 (30.7%) were observation stays. The majority of unplanned rehospitalizations (72%) were for cardiovascular reasons. Variation in hospital rates of 30-day unplanned rehospitalization ranged from 5.4% to 20.0%, with a median of 10.7%. After multivariable modeling, the factors most strongly associated with unplanned rehospitalization were baseline quality of life and depression, followed by index hospital length of stay. CONCLUSIONS Early unplanned rehospitalizations are common after acute myocardial infarction, and close to one third were classified as an observation stay. Predischarge and postdischarge assessments of overall, not just cardiovascular, health and strategies to optimize patient functional status may help to reduce unplanned rehospitalizations. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01088503.
Collapse
Affiliation(s)
- Connie N Hess
- From Duke Clinical Research Institute, Durham, NC (C.N.H., T.Y.W., L.A.M., E.P.P.); Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (J.C.M.); Lilly USA LLC, Indianapolis, IN (M.B.E., M.E.Z.); Cedars Sinai Heart Institute, Los Angeles, CA (T.D.H.); and Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.).
| | - Tracy Y Wang
- From Duke Clinical Research Institute, Durham, NC (C.N.H., T.Y.W., L.A.M., E.P.P.); Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (J.C.M.); Lilly USA LLC, Indianapolis, IN (M.B.E., M.E.Z.); Cedars Sinai Heart Institute, Los Angeles, CA (T.D.H.); and Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.)
| | - Lisa A McCoy
- From Duke Clinical Research Institute, Durham, NC (C.N.H., T.Y.W., L.A.M., E.P.P.); Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (J.C.M.); Lilly USA LLC, Indianapolis, IN (M.B.E., M.E.Z.); Cedars Sinai Heart Institute, Los Angeles, CA (T.D.H.); and Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.)
| | - John C Messenger
- From Duke Clinical Research Institute, Durham, NC (C.N.H., T.Y.W., L.A.M., E.P.P.); Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (J.C.M.); Lilly USA LLC, Indianapolis, IN (M.B.E., M.E.Z.); Cedars Sinai Heart Institute, Los Angeles, CA (T.D.H.); and Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.)
| | - Mark B Effron
- From Duke Clinical Research Institute, Durham, NC (C.N.H., T.Y.W., L.A.M., E.P.P.); Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (J.C.M.); Lilly USA LLC, Indianapolis, IN (M.B.E., M.E.Z.); Cedars Sinai Heart Institute, Los Angeles, CA (T.D.H.); and Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.)
| | - Marjorie E Zettler
- From Duke Clinical Research Institute, Durham, NC (C.N.H., T.Y.W., L.A.M., E.P.P.); Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (J.C.M.); Lilly USA LLC, Indianapolis, IN (M.B.E., M.E.Z.); Cedars Sinai Heart Institute, Los Angeles, CA (T.D.H.); and Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.)
| | - Timothy D Henry
- From Duke Clinical Research Institute, Durham, NC (C.N.H., T.Y.W., L.A.M., E.P.P.); Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (J.C.M.); Lilly USA LLC, Indianapolis, IN (M.B.E., M.E.Z.); Cedars Sinai Heart Institute, Los Angeles, CA (T.D.H.); and Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.)
| | - Eric D Peterson
- From Duke Clinical Research Institute, Durham, NC (C.N.H., T.Y.W., L.A.M., E.P.P.); Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (J.C.M.); Lilly USA LLC, Indianapolis, IN (M.B.E., M.E.Z.); Cedars Sinai Heart Institute, Los Angeles, CA (T.D.H.); and Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.)
| | - Gregg C Fonarow
- From Duke Clinical Research Institute, Durham, NC (C.N.H., T.Y.W., L.A.M., E.P.P.); Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (J.C.M.); Lilly USA LLC, Indianapolis, IN (M.B.E., M.E.Z.); Cedars Sinai Heart Institute, Los Angeles, CA (T.D.H.); and Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.)
| |
Collapse
|
29
|
Zettler ME, Merchant MA, Pierce GN. Augmented cell cycle protein expression and kinase activity in atherosclerotic rabbit vessels. Exp Clin Cardiol 2010; 15:e139-e144. [PMID: 21264072 PMCID: PMC3016074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Cell proliferation within a primary atherosclerotic plaque is controversial. Identifying changes in cell cycle protein expression and the activities of their related kinases would provide valuable evidence of mitotic activity in the atherosclerotic lesion. Oxidized low-density lipoprotein has been shown to induce a significant increase in the total number of rabbit vascular smooth muscle cells in culture. In the present study, whole aortic cell extracts were harvested from rabbits fed a cholesterol-supplemented diet for eight weeks to induce modest plaque development, or 16 weeks to induce later, more severe plaque progression. Expression levels of cyclin A, cyclin-dependent kinase 4 (Cdk 4) and proliferating cell nuclear antigen were measured, as well as the activities of Cdk 4, Cdk 2 and Cdk 1. At both time points, the expression levels of cyclin A, Cdk 4 and proliferating cell nuclear antigen were significantly elevated. The activity of all three Cdks was also increased. There were no significant differences between moderate and more severe atherosclerosis. Surprisingly, tissues that neighboured the plaques, but did not show visible plaque formation on the vessel surface, also had significantly elevated cyclin A expression levels, but not as high as in the plaque areas. In conclusion, the primary atherosclerotic plaque exhibited elevated mitotic activity as shown by increased expression levels and activities of several cell cycle proteins. Expression levels were similar during moderate and severe atherosclerosis, and were even detected in nonatherosclerotic vascular tissue bordering the plaque.
Collapse
Affiliation(s)
| | | | - Grant N Pierce
- Correspondence: Dr Grant N Pierce, St Boniface General Hospital Research Centre, 351 Tache Avenue, Winnipeg, Manitoba R2H 2A6. Telephone 204-235-3206, fax 204-235-0793, e-mail
| |
Collapse
|
30
|
Kaul N, Kreml R, Austria JA, Richard MN, Edel AL, Dibrov E, Hirono S, Zettler ME, Pierce GN. A comparison of fish oil, flaxseed oil and hempseed oil supplementation on selected parameters of cardiovascular health in healthy volunteers. J Am Coll Nutr 2008; 27:51-8. [PMID: 18460481 DOI: 10.1080/07315724.2008.10719674] [Citation(s) in RCA: 99] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVE The impact of dietary polyunsaturated fatty acids (PUFAs) of the n-6 and n-3 series on the cardiovascular system is well documented. To directly compare the effects of three dietary oils (fish, flaxseed and hempseed) given in concentrations expected to be self-administered in the general population on specific cardiovascular parameters in healthy volunteers. DESIGN 86 healthy male and female volunteers completed a 12 week double blinded, placebo controlled, clinical trial. They were randomly assigned to one of the four groups. Subjects were orally supplemented with two 1 gm capsules of placebo, fish oil, flaxseed oil or hempseed oil per day for 12 weeks. RESULTS Plasma levels of the n-3 fatty acids docosahexanoic acid and eicosapentanoic acid increased after 3 months supplementation with fish oil. Alpha linolenic acid concentrations increased transiently after flaxseed supplementation. However, supplementation with hempseed oil did not significantly alter the concentration of any plasma fatty acid. The lipid parameters (TC, HDL-C, LDL-C and TG) did not show any significant differences among the four groups. Oxidative modification of LDL showed no increase in lag time over the 12 wk period. None of the dietary interventions induced any significant change in collagen or thrombin stimulated platelet aggregation and no increase in the level of inflammatory markers was observed. CONCLUSION From a consumer's perspective, ingesting 2 capsules of any of these oils in an attempt to achieve cardiovascular health benefits may not provide the desired or expected result over a 3 month period.
Collapse
Affiliation(s)
- Nalini Kaul
- Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Hospital Research Centre, University of Manitoba, Winnipeg, Manitoba, Canada R2H 2A6
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Kandzari DE, Dery JP, Armstrong PW, Douglas DA, Zettler ME, Hidinger GKG, Friesen AD, Harrington RA. MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury. Expert Opin Investig Drugs 2006; 14:1435-42. [PMID: 16255681 DOI: 10.1517/13543784.14.11.1435] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Despite the overall efficacy of mechanical reperfusion therapies, such as percutaneous coronary intervention and coronary artery bypass graft surgery, in reducing the morbidity and mortality that is associated with acute ischaemic syndromes, many of the treated patients develop ischaemia-reperfusion injury due to impaired microvascular integrity, embolisation of atherothrombotic debris and/or disrupted end-organ metabolism. MC-1 is an investigational drug from Medicure, Inc. In preclinical models of ischaemia and ischaemia-reperfusion injury, treatment with MC-1 has demonstrated significant cardio- and neuroprotective effects. Although the pharmacological activity of MC-1 may involve multiple mechanisms, research suggests that at least part of the protective effect may be mediated through its actions on purinergic receptors. Early clinical experience with MC-1 also appears to be promising: in a recent Phase II evaluation, treatment with MC-1 was associated with a statistically significant reduction in periprocedural infarct size (as measured by area under the curve creatine kinase-myocardial band) among high-risk patients undergoing elective percutaneous coronary intervention. Based on these findings, larger, randomised trials to confirm the safety and efficacy of MC-1 in the setting of coronary artery revascularisation with coronary artery bypass graft, acute coronary syndromes and stroke are ongoing or in development. These forthcoming evaluations should clarify the safety and efficacy of MC-1 and improve the understanding regarding its potential therapeutic role in a variety of clinical settings and indications.
Collapse
|
32
|
Zettler ME, Prociuk MA, Austria JA, Zhong G, Pierce GN. Oxidized low-density lipoprotein retards the growth of proliferating cells by inhibiting nuclear translocation of cell cycle proteins. Arterioscler Thromb Vasc Biol 2004; 24:727-32. [PMID: 14764420 DOI: 10.1161/01.atv.0000120373.95552.aa] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Our study tested the hypothesis that the mitogenic effect of oxidized low-density lipoprotein (oxLDL) on vascular cells may be further enhanced by the presence of cytokines and growth factors known to be present in the atherosclerotic environment. METHODS AND RESULTS Quiescent fibroblasts and vascular smooth muscle cells were treated with 10 or 50 microg/mL minimally-oxidized LDL in combination with serum for 24 or 48 hours. Surprisingly, these cells showed inhibited release from growth arrest and a significant reduction in the number of cells completing the cell cycle when compared with cells treated with serum alone. This was not due to an induction of apoptosis. The antiproliferative effects were not closely associated with changes in the expression of cell cycle proteins. Instead, oxLDL inhibited the translocation of cell cycle proteins cell division cycle (Cdc) 2, cyclin-dependent kinase (Cdk) 2, Cdk 4, Cyclin A, Cyclin B1, Cyclin D1, and proliferative cell nuclear antigen (PCNA) into the nucleus, as compared with separate treatments with serum alone. Kinase activation associated with specific cell cycle proteins was also inhibited by oxLDL. CONCLUSIONS oxLDL, in the presence of serum, has a surprising inhibitory effect on cell proliferation that occurs through an inhibition of import of cell cycle proteins into the cell nucleus.
Collapse
MESH Headings
- Active Transport, Cell Nucleus/drug effects
- Animals
- Apoptosis
- Arteriosclerosis/metabolism
- Cell Cycle/drug effects
- Cell Cycle Proteins/metabolism
- Cell Division/drug effects
- Cells, Cultured/drug effects
- Cells, Cultured/metabolism
- Culture Media, Serum-Free/pharmacology
- Depression, Chemical
- Dose-Response Relationship, Drug
- Fibroblasts/drug effects
- Fibroblasts/metabolism
- Growth Substances/pharmacology
- Humans
- Lipoproteins, LDL/pharmacology
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Myocytes, Smooth Muscle/drug effects
- Myocytes, Smooth Muscle/metabolism
- Rabbits
Collapse
Affiliation(s)
- Marjorie E Zettler
- Cell Biology Laboratory, Division of Stroke and Vascular Disease, St Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada
| | | | | | | | | |
Collapse
|
33
|
Zettler ME, Prociuk MA, Austria JA, Massaeli H, Zhong G, Pierce GN. OxLDL stimulates cell proliferation through a general induction of cell cycle proteins. Am J Physiol Heart Circ Physiol 2003; 284:H644-53. [PMID: 12529257 DOI: 10.1152/ajpheart.00494.2001] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Oxidized low-density lipoprotein (oxLDL) may be involved in atherosclerosis by stimulating proliferation of cells in the vessel wall. The purpose of this study was to identify the mechanism by which oxLDL induces proliferation. Quiescent human fibroblasts and rabbit smooth muscle cells were treated with 0, 10, or 50 microg/ml oxLDL for 24-48 h. This resulted in significant increases in total cell counts at both concentrations of oxLDL, at both time points, for both types of cells. Western blot analysis revealed that oxLDL-stimulated cell proliferation was associated with significant increases in the expression of proteins that regulate entry into and progression through the cell cycle [cell division cycle 2, cyclin-dependent kinase (cdk) 2, cdk 4, cyclin B1, cyclin D1, and PCNA]. Surprisingly, the expression of cell cycle inhibitors (p21 and p27) was stimulated by oxLDL as well, but this was to a lesser extent than the effects on cell cycle-activating proteins. OxLDL also induced nuclear localization of all cell cycle proteins examined. The similar effects of oxLDL on the translocation and expression of both cell cycle-activating and -inhibiting proteins may explain the controlled proliferative phenomenon observed in atherosclerosis as opposed to the more rapid proliferative event characteristic of cancer.
Collapse
Affiliation(s)
- Marjorie E Zettler
- Cell Biology Laboratory, Division of Stroke and Vascular Disease, St. Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada R2H 2A6
| | | | | | | | | | | |
Collapse
|
34
|
Zettler ME, Austria J, Pierce GN. Signaling pathways involved in OXLDL-Induced mitogenesis. J Mol Cell Cardiol 2001. [DOI: 10.1016/s0022-2828(01)90542-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Zettler ME, Austria J, Pierce GN. Growth inhibitory effects of OXLDL on serum-treated cells. J Mol Cell Cardiol 2001. [DOI: 10.1016/s0022-2828(01)90540-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Abstract
Progression of the eukaryotic cell through the cell cycle to induce cell proliferation is a fundamental event in developmental growth processes. Specific cell cycle proteins are critical for either inducing or suppressing the cell cycle. These proteins, therefore, have been found to be key players in regulating cell proliferation in diseases like cancer and atherosclerosis. The present manuscript reviews the process of cell proliferation in atherosclerosis and the data that have implicated the various cell cycle proteins in restenotic and atherosclerotic vascular disease.
Collapse
Affiliation(s)
- M E Zettler
- Department of Physiology, St. Boniface General Hospital Research Center, University of Manitoba, Winnipeg, Canada
| | | |
Collapse
|